CHILDHOOD NHL IN SWITZERLAND - INCIDENCE AND SURVIVAL OF 120 STUDY AND 42 NON-STUDY PATIENTS

被引：47

作者：

WAGNER, HP ^{[1
]}

DINGELDEINBETTLER, I ^{[1
]}

BERCHTHOLD, W ^{[1
]}

LUTHY, AR ^{[1
]}

HIRT, A ^{[1
]}

PLUSS, HJ ^{[1
]}

BECK, D ^{[1
]}

WYSS, M ^{[1
]}

SIGNER, E ^{[1
]}

IMBACH, P ^{[1
]}

FELDGES, A ^{[1
]}

BLEHER, EA ^{[1
]}

PLASCHKES, J ^{[1
]}

BRINER, J ^{[1
]}

LEIBUNDGUT, K ^{[1
]}

VONDERWEID, N ^{[1
]}

机构：

[1] UNIV BERN,INSELSPITAL,KINDERKLIN,SWISS PEDIAT ONCOL GRP,CH-3010 BERN,SWITZERLAND

来源：

MEDICAL AND PEDIATRIC ONCOLOGY | 1995年 / 24卷 / 05期

关键词：

NON-HODGKINS LYMPHOMA; PEDIATRIC; INCIDENCE; TREATMENT; POPULATION-BASED;

D O I：

10.1002/mpo.2950240503

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Based on the Swiss Pediatric Oncology Group (SPOG) cancer registry data during 1981-1991, a high average incidence of 8 new NHL per million children younger than 15 years per year was found. Of 162 children with NHL registered in 1976-1991, 120 were study patients, i.e., officially registered and treated according to SPOG or Pediatric Oncology Group (POG) protocols, while 42 were non-study patients, i.e., patients not officially enrolled on protocols. Overall, 91 of 120 (76%) study patients remained alive. Seventy-nine study patients were treated according to older SPOG protocols, and 53 (67%) of these survived, while 38 of 41 (93%) study patients treated according to newer POG protocols remained alive (P = 0.0068). Only 22 (52%) of the 42 non-study patients survived (P = 0.0001). There was no improvement if the survival of non-study patients before and since 1986 was compared. Population-based treatment results in Switzerland were similar to those in the United Kingdom. They provided an important base for the development of future treatment strategies. (C) 1995 Wiley-Liss, Inc.

引用

页码：281 / 286

页数：6

共 28 条

[1]

Wagner HP, Bleher EA, Burki K, Delaleu B, Gretillat P, Kuhner U, Pedrinis E, Malignant non‐Hodgkin's lymphoma (NHL) in childhood. Retrospective analysis of 34 cases, Helv Pediatr Acta, 32, pp. 331-342, (1977)

[2]

Wollner N, Burchenal JH, Liebermann PH, Exelby P, D'Angio G, Murphy ML, Non‐Hodgkin's lymphoma in children. A comparative study of two modalities of therapy, Cancer, 37, pp. 123-134, (1976)

[3]

Baumgartner C, Bleher EA, Brun del Re G, Bucher U, Deubelbeiss KA, Greiner R, Hirt A, Imbach P, Luthi A, Odavic R, Wagner HP, Autologous bone marrow transplantation in the treatment of children and adolescents with advanced malignant tumors, Med Pediatr Oncol, 12, pp. 104-111, (1984)

[4]

Morin G, Ackermann-Liebrich U, Imbach P, Childhood leukemia in Switzerland, comparison of different sources of data, Soz Präventiv Med, 38, pp. 196-201, (1993)

[5]

Murphy SB, Classification, staging and end results of treatment of childhood non‐Hodgkin's lymphomas: Dissimilarities from lymphomas in adults, Semin Oncol, 7, pp. 332-339, (1980)

[6]

Wagner HP, Feldges A, Imbach P, Pluss HJ, Sartorius J, Wyss M, Malignes Nicht‐Hodgkin Lymphom im Kindesalter. Behandlungsresultate bei 47 Patienten, Schweiz Med Wochenschr, 109, pp. 797-801, (1979)

[7]

Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy SB, Results of treatment of childhood localized non‐Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy, N Engl J Med, 322, pp. 1169-1174, (1990)

[8]

Sullivan MP, Brecker M, Ramirez I, Ragab A, Hvizdala E, Phallen J, Shuster J, Berard C, Crist W, Vietti T, High‐dose cyclophosphamide‐high‐dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: Results of a Pediatric Oncology Group study, Am J Pediatr Hematol Oncol, 13, pp. 288-295, (1991)

[9]

Murphy SB, Bowman P, Sullivan MP, Shuster J, Berard C, Results of Pediatric Oncology Group (POG) 8616: A randomized trial of two forms of therapy for stage III diffuse, small non‐cleaved cell lymphoma in children, Proc ASCO, 11, (1992)

[10]

Ziegler JL, Burkitt's lymphoma, N Engl J Med, 305, pp. 734-745, (1981)

← 1 2 3 →